期刊
JOURNAL OF PHARMACEUTICAL SCIENCES
卷 99, 期 8, 页码 3552-3560出版社
JOHN WILEY & SONS INC
DOI: 10.1002/jps.22113
关键词
anticancer drugs; cancer nanotechnology, chemotherapeutic engineering; nanomedicine, oral bioavailability
资金
- Singapore Cancer Syndicate, BMRC [U0028]
- National University of Singapore [R279-000-226-112]
This work evaluates the effects of paclitaxel loaded polymeric nanoparticles (NPs) composed of poly(D,L-lactic-co-glycolic acid) (PLGA) with vitamin E TPGS as emulsifier for oral chemotherapy NPs prepared by a modified solvent extraction/evaporation technique were observed in spherical shape of 200-300 rim diameter with a high drug encapsulation efficiency (EE) of 80.9%. The TPGS-emulsffied PLGA NPs formulation of paclitaxel was found of great advantages over that of Taxol (R). The in vitro viability experiment showed that the NP formulation could be 1 28, 1.38, 1 12 times more effective than Taxol (R) after 24, 48, 72 h incubation with MGF-7 human breast cancer cell line at 2.5 mu g/mL paclitaxel concentration In VIVO evaluation confirmed the advantages of the TPGS-emulsified PLGA NP formulation versus Taxol (R) in promoting oral bioavailability of paclitaxel. Such a NP formulation achieved more than 10 times higher oral bioavailability than Taxol (R), which resulted 9.74-fold higher therapeutic effect and 12.56-fold longer sustainable therapeutic time than Taxol (R) The present proof-of-concept experimental data proved that the formulation of vitamin E TPGS emulsified PLGA NPs is a promising approach for paclitaxel oral administration. Oral chemotherapy by NPs formulation is feasible. (C) 2010 Wiley-Liss, Inc and the American Pharmacists Association J Pharm Sci 99 3552-3560. 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据